Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Spain flag Spain · Delayed Price · Currency is EUR
84.75
+0.15 (0.18%)
At close: Feb 27, 2026
54.65%
Market Cap 4.33B
Revenue (ttm) 724.20M
Net Income (ttm) 121.15M
Shares Out 51.15M
EPS (ttm) 2.37
PE Ratio 35.78
Forward PE 27.52
Dividend 0.94 (1.10%)
Ex-Dividend Date Jul 14, 2025
Volume 155,932
Average Volume 142,709
Open 84.40
Previous Close 84.60
Day's Range 83.85 - 85.00
52-Week Range 45.52 - 85.00
Beta 0.24
RSI 84.14
Earnings Date Feb 25, 2026

About BME:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,... [Read more]

Sector Healthcare
Founded 1946
Employees 2,188
Stock Exchange Madrid Stock Exchange
Ticker Symbol ROVI
Full Company Profile

Financial Performance

In 2024, BME:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial Statements

News